TrialClinical drug investigation2014

Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.

Nobuya Inagaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.